TekturnaTreatment for Hypertension
Novartis Announces Three-Month Extension of US Regulatory Review Period for Tekturna
* Tekturna seeking to become first drug in a new class of high blood pressure medicines
* Extension provides FDA time to review new clinical data supporting safety profile of Tekturna
* Novartis committed to working closely with FDA to gain approval for Tekturna, which has been studied in more than 6,000 people to date
BASEL, Switzerland, December 14, 2006 - Novartis announced today that the US regulatory review period has been extended by up to three months for Tekturna (aliskiren), which was submitted for approval earlier in 2006 to become the first in a new class of high blood pressure medicines for more than a decade.
The extension will provide the US Food and Drug Administration (FDA) with time to consider additional clinical data submitted by Novartis in early December. These data come from a study involving 30 healthy volunteers who received Tekturna at the proposed 300 mg once-daily dose for eight weeks to study potential changes of the colonic mucosa. Analysis of the data indicated that Tekturna did not induce any changes in the mucosal lining of the colon, as evaluated by colonoscopy and biopsies.
Novartis is confident that providing this additional information to the FDA will help secure approval for Tekturna in the US and allow for this important therapy to be offered to patients seeking to gain control of high blood pressure. Tekturna was developed in collaboration with Speedel.
Posted: December 2006
- Tekturna - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US - March 6, 2007
- New Drug Application (NDA) for Rasilez (Aliskiren), an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for Review by the US FDA - April 20, 2006